Immulite System Estradiol Assay (2020-02-11) — recall 63208
Health Canada — Medical Devices · Canada · 2020-03-06 · Type II
🏛Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked above. No AI-generated text appears on this page. How we use AI →
Reported risk: High discordant Estradiol results for some patients have been reported in conjunction with the reported IMMULITE Estradiol Assays. Siemens Healthineers has determined kit lots 501 and above, released in July 2018 for the IMMULITE systems are potentially affected. Siemens investigation indicates that some patient samples could potentially contain an unidentified interferent which is causing an increase in estradiol concentration in the IMMULTE Estradiol Assay. The majority of the complaints received by Siemens are form the United States. Based on available data the issue has been observed only with customer returned patient samples. Quality control materials will not detect this issue. Siemens is actively working to determine the root cause. Siemens has currently suspended shipment of IMMULITE Systems Estradiol assay.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.